We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Abbott Diagnostics

Abbott Diagnostics provides medical diagnostic instruments, tests, automation and informatics solutions, including cl... read more Featured Products: More products

Download Mobile App




Highly Sensitive Thyroglobulin Chemiluminescent Microparticle Immunoassay Evaluated

By LabMedica International staff writers
Posted on 20 Jul 2022
Print article
Image: The Alinity I Immunoassay analyzer (Photo courtesy of Abbott)
Image: The Alinity I Immunoassay analyzer (Photo courtesy of Abbott)

Differentiated thyroid cancer (DTC) is the most frequent endocrine malignancy. Standard treatment of DTC is thyroidectomy plus, for high risk cases, radioactive iodine ablation therapy, and pharmacological suppression of TSH.

Thyroglobulin (Tg) measurement is an essential diagnostic element of the follow-up and management of patients with differentiated thyroid cancer (DTC), as the 660 kDa glycoprotein is exclusively produced by benign or well-differentiated malignant thyroid cells. Tg is the matrix for synthesis and storage form of thyroxine (T4) and triiodothyronine (T3) within the thyroid follicles.

Clinical Biochemists at the University Health Network (UHN, Toronto, ON, Canada) participated in a three-center study, Tg values of 447 routine patient samples, characterized for the presence of anti-Tg. Mostly fresh samples from routine Tg requests were used. In addition, frozen samples, and precision and limit of quantitation patient pools and controls were utilized.

Samples were measured on ARCHITECT i2000SR (Abbott, Abbott Park, IL, USA) at three sites and Abbott’s Alinity i analyzer at one site using respective Tg and anti-Tg reagents, calibrators, and controls. For method comparison, samples were measured on a cobas 411 (Roche Diagnostics, Rotkreuz, Switzerland) at all three sites and on UniCel DxI 800 (Beckman Coulter, Brea, CA, USA) at one site using respective reagents, calibrators, and controls. Anti-Tg status was determined using Alinity i anti-Tg assay or ARCHITECT anti-Tg.

Serum Tg measured using with ARCHITECT was compared with the Roche Elecsys Tg II results. In total, 447 patient samples were analyzed for ARCHITECT and Roche with 56 samples positive for anti-Tg (cutoff 4.1 IU/mL). ARCHITECT Tg concentrations were ranging from 0.09 to 486 ng/mL for anti-Tg-negative and 0.09 to 341 ng/mL for anti-Tg-positive samples. Roche Tg values were closely correlated, with a correlation coefficient greater than 0.98 and a slope within 0.9–1.1 for anti-Tg-negative and anti-Tg-positive samples. Limit of quantitation (LoQ) was verified to be less than or equal to 0.1 ng/mL confirming that the Tg assay on ARCHITECT and Alinity was highly sensitive.

The authors concluded that the Abbott Thyroglobulin assay, which is standardized to the human thyroglobulin reference material (CRM-457), demonstrated a high correlation to the Roche and Beckman Tg assays, though good agreement of absolute values was only observed between Abbott and Roche. Strength of correlation and slope were not affected by the presence of anti-Tg indicating that all assays included in the study have a similar susceptibility to anti-Tg. The study was published on July 15, 2022 in the Journal of Clinical Laboratory Analysis.

Related Links:
University Health Network 
Abbott
Roche Diagnostics 
Beckman Coulter 

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Fixed Speed Tube Rocker
GTR-FS
New
Hemoglobin/Haptoglobin Assay
IDK Hemoglobin/Haptoglobin Complex ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.